146 related articles for article (PubMed ID: 35378464)
1. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.
Deng X; Li X; Guo X; Lu Y; Xie Y; Huang X; Lin J; Tan W; Wang C
Neoplasia; 2022 Jun; 28():100788. PubMed ID: 35378464
[TBL] [Abstract][Full Text] [Related]
2. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor-infiltrating Ly6G
Chang CJ; Yang YH; Chiu CJ; Lu LC; Liao CC; Liang CW; Hsu CH; Cheng AL
Int J Cancer; 2018 May; 142(9):1878-1889. PubMed ID: 29266245
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
[TBL] [Abstract][Full Text] [Related]
5. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
Chen J; Sun S; Li H; Cai X; Wan C
Front Immunol; 2024; 15():1373321. PubMed ID: 38596684
[TBL] [Abstract][Full Text] [Related]
6. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
9. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
10. Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice.
Feng XY; Chen BC; Li JC; Li JM; Li HM; Chen XQ; Liu D; Li RT
Phytomedicine; 2021 Dec; 93():153779. PubMed ID: 34638030
[TBL] [Abstract][Full Text] [Related]
11. Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation.
Tao H; Liu M; Wang Y; Luo S; Xu Y; Ye B; Zheng L; Meng K; Li L
Front Immunol; 2021; 12():609295. PubMed ID: 33717093
[TBL] [Abstract][Full Text] [Related]
12. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
Xu M; Zhao Z; Song J; Lan X; Lu S; Chen M; Wang Z; Chen W; Fan X; Wu F; Chen L; Tu J; Ji J
Exp Cell Res; 2017 Feb; 351(2):142-149. PubMed ID: 28109867
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
[TBL] [Abstract][Full Text] [Related]
14. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
[TBL] [Abstract][Full Text] [Related]
15. Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through β-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades.
Cao M; Huang W; Chen Y; Li G; Liu N; Wu Y; Wang G; Li Q; Kong D; Xue T; Yang N; Liu Y
Int J Cancer; 2021 Jul; 149(2):460-472. PubMed ID: 33751565
[TBL] [Abstract][Full Text] [Related]
16. IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment.
Mei Y; Zhu Y; Yong KSM; Hanafi ZB; Gong H; Liu Y; Teo HY; Hussain M; Song Y; Chen Q; Liu H
Cell Rep; 2024 Mar; 43(3):113835. PubMed ID: 38412100
[TBL] [Abstract][Full Text] [Related]
17. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma.
Wang N; Tan HY; Lu Y; Chan YT; Wang D; Guo W; Xu Y; Zhang C; Chen F; Tang G; Feng Y
Signal Transduct Target Ther; 2021 Feb; 6(1):86. PubMed ID: 33633112
[TBL] [Abstract][Full Text] [Related]
18. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance.
Chang YS; Su CW; Chen SC; Chen YY; Liang YJ; Wu JC
Cells; 2022 Feb; 11(4):. PubMed ID: 35203285
[TBL] [Abstract][Full Text] [Related]
20. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
